摘要
目的研究寒痹方(黄芪、制川乌、全蝎、蜈蚣、地龙)对佐剂型类风湿性关节炎(RA)大鼠的治疗作用,并探讨其机制。方法建立佐剂型大鼠RA模型后,大鼠分为正常组,模型组,地塞米松阳性组,宝光风湿液(羌活、独活、川芎等)阳性组,寒痹方低,高剂量组,测量大鼠足跖容积和肿胀度。ELISA法检测血清白介素-1β(IL-1β)和肿瘤坏死因子-α(TNF-α);四甲基偶氮唑盐(MTT)法测定淋巴细胞的增殖能力;HE染色检查关节滑膜组织病理学变化;免疫组化法检测滑膜组织中白介素-17(IL-17)和TNF-α的表达。结果寒痹方可显著缓解RA大鼠的足跖肿胀。与模型组相比,寒痹方可显著缓解RA大鼠的滑膜腔炎症,下调血清及滑膜组织中IL-1β和TNF-α的表达,抑制淋巴细胞增殖。以上指标在低、高剂量寒痹方组之间无统计学差异,寒痹方整体效果与宝光风湿液相当,但不及地塞米松。结论寒痹方具有较强的抗RA作用,其机制可能与抑制淋巴细胞增殖以及降低炎性细胞因子的分泌有关。
AIM To research the therapeutic effects of Hanbi Formula（Astragali Radix,Aconiti Radix cocta,Scorpio,Scolopendrap and Pheretima） on adjuvant-induced arthritis rats（RA） and its mechanism of action.METHODS RA rat models were established by using Freund’s adjuvant,and then the rats were divided into six groups,namely control group,model group,dexamethasone positive group,Baoguang Fengshi Liquid（Notopterygii Rhizoma et Radix,Radix angelicae pubescentis,Chuanxiong Rhizoma,etc.） positive group,and low,high doses of Hanbi Formula groups.The volume and swelling of toes were measured.The interleukin-1β（IL-1β） and tumor necrosis factor-α（TNF-α） of serum were detected by ELISA;the proliferative capacity of lymphocytes was tested by methyl thiazolyl tetrazolium（MTT） method;synovial tissue was histopathologically examined with HE staining.Finally,the expressions of interleukin-17（IL-17） and TNF-α in synovial tissue were determined by immunohistochemical assays.RESULTS Hanbi Formula could significantly relieve toe swelling of RA rats.Compared with the model group,Hanbi Formula could significantly alleviate synovitis in rats with RA,down-regulate the expressins of IL-1β and TNF-α in serum and synovial tissue,and inhibit lymphocyte proliferation.There were no significant differences in above indices between low-dose and high-dose Hanbi Formula groups,which was quite with Baoguang Fengshi Liquid,but less than dexamethasone.CONCLUSION Hanbi Formula possesses an obvious function of anti-RA,and its mechanism may be related to the inhibition of lymphocyte proliferation and reducing secretion of inflammatory cytokines.
作者
张世玲
张世梅
李娟
卢军
照日格图
程路峰
ZHANG Shi-ling ZHANG Shi-mei LI Juan Zhao-ri-ge-tu CHENG Lu-feng(Department of Pharmacy, Hospital of Traditional Chinese Medicine Affiliated to Xinjiang Medical University, Urumqi 830002, China Depart- ment of Pharmacy, Yili Friendship Hospital, Yili 835000, China Department of Rheumatism, Hospital of Traditional Chinese Medicine Affiliated to Xinjiang Medical University, Urumqi 830002, China Department of Pharmacology, School of Preclinical Medicine of Xinjiang Medical University, Urumqi 830011, China)
出处
《中成药》
CAS
CSCD
北大核心
2017年第3期445-450,共6页
Chinese Traditional Patent Medicine
基金
国家自然科学基金资助项目(81360491)
